Clinical Trials

Stomach Neoplasms

NCT07050043 2025-07-03

LEDANG

Phase 3 Recruiting

123 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02446652 2025-05-29

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

Phase 3 Withdrawn

Uterine Cervical Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Phase 1/2 Recruiting

51 enrolled

Phase 2 Not yet recruiting

Stomach Neoplasms

NCT06670911 2025-02-24

ACCESS-I

Phase 2 Recruiting

44 enrolled

Recurrence

NCT05628610 2024-08-13

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

130 enrolled

Phase 2 Active not recruiting

Esophageal Neoplasms

NCT06531447 2024-08-01

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

200 enrolled

Phase 2 Not yet recruiting

Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement, Breast Neoplasms

NCT06066216 2024-01-23

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

45 enrolled

Phase EARLY_PHASE1 Unknown

Endometrial Neoplasms

NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

40 enrolled

EGFR Positive Non-small Cell Lung Cancer

NCT06197438 2024-01-09

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

36 enrolled

Phase 2 Not yet recruiting

Stomach Neoplasms

NCT06149767 2023-11-29

Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

26 enrolled

Uterine Cervical Neoplasms

NCT05832827 2023-10-23

Artemis

Phase 2 Recruiting

35 enrolled

Thymoma

NCT05751265 2023-06-22

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

39 enrolled

Stomach Neoplasms

NCT04063683 2021-08-24

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

47 enrolled

Esophageal Squamous Cell Carcinoma

NCT05013697 2021-08-19

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

48 enrolled

Esophageal Neoplasms

NCT02414685 2020-08-07

TIP

Phase 2 Completed

19 enrolled

Neoplasms, Germ Cell and Embryonal

NCT02741856 2018-10-25

SCOPE2

Phase 2/3 Unknown

584 enrolled

Esophageal Neoplasms

NCT02924909 2018-03-20

QUIMERA

50 enrolled

Esophageal Neoplasms

NCT01843829 2014-03-24

NeoSCOPE

85 enrolled

Esophageal Neoplasms

NCT01654146 2012-07-31

ICON8

Phase 3 Unknown

1,485 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00532857 2012-01-04

PGH

Phase 2 Completed

53 enrolled

Breast Neoplasms

NCT01133912 2012-01-04

PGT

Phase 1 Completed

13 enrolled

Breast Neoplasms

NCT01169870 2012-01-04

Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT00686322 2011-09-15

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Phase 4 Completed

6 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00532285 2011-06-23

Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer

Phase 2 Terminated

44 enrolled

Breast Neoplasms

NCT00453167 2010-07-12

Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer

Phase 2 Completed

35 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT00453323 2010-07-12

Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer

33 enrolled